Review: Perbandingan antara Standard Half-Life (SHL) dan Extended Half-Life (EHL) Replacement Therapy berbasis Real-World Evidence (RWE)

Hemophilia is a common hereditary coagulation blood disorder due to the deficiency activity of clotting factors. divided into two, namely hemophilia A and B. Among all treatments, standard half-life (SHL) extended (EHL) factor replacement products are most commonly used. This study aimed review real-world evidence on comparison SHL EHL. literature search was conducted in PubMed google scholar published from 2017 2021. There were 10 articles that met criteria. Based synthesis results, total proportion patients using EHL concentrates for both on‐demand prophylactic therapy increased. Recent reveals may reduce number infusions, increase trough levels, substantially decrease annual bleeding rate. Efficacy-wise, EHLs unquestionably have better performances than SHLs; however, seem be too expensive utilized as primary care hemophilia. However, economic aspect switching still required more in-depth studies.